JP2017526629A - 血液系悪性腫瘍を治療、診断および予後判定するための方法 - Google Patents

血液系悪性腫瘍を治療、診断および予後判定するための方法 Download PDF

Info

Publication number
JP2017526629A
JP2017526629A JP2016575341A JP2016575341A JP2017526629A JP 2017526629 A JP2017526629 A JP 2017526629A JP 2016575341 A JP2016575341 A JP 2016575341A JP 2016575341 A JP2016575341 A JP 2016575341A JP 2017526629 A JP2017526629 A JP 2017526629A
Authority
JP
Japan
Prior art keywords
htr
type
inhibitor
cells
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016575341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526629A5 (enExample
Inventor
リスエニョ，ルース ムニョス
リスエニョ，ルース ムニョス
Original Assignee
インスティテュート デ レセルカ コントラ ラ ロイセミア ジョセップ カレーラス
インスティテュート デ レセルカ コントラ ラ ロイセミア ジョセップ カレーラス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティテュート デ レセルカ コントラ ラ ロイセミア ジョセップ カレーラス, インスティテュート デ レセルカ コントラ ラ ロイセミア ジョセップ カレーラス filed Critical インスティテュート デ レセルカ コントラ ラ ロイセミア ジョセップ カレーラス
Publication of JP2017526629A publication Critical patent/JP2017526629A/ja
Publication of JP2017526629A5 publication Critical patent/JP2017526629A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016575341A 2014-06-27 2015-06-26 血液系悪性腫瘍を治療、診断および予後判定するための方法 Withdrawn JP2017526629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382249.2A EP2959904A1 (en) 2014-06-27 2014-06-27 Methods for treating, diagnosing and prognosing a haematological malignancy
EP14382249.2 2014-06-27
PCT/EP2015/064571 WO2015197839A1 (en) 2014-06-27 2015-06-26 Methods for treating, diagnosing and prognosing a haematological malignancy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020019451A Division JP6846551B2 (ja) 2014-06-27 2020-02-07 血液系悪性腫瘍を治療、診断および予後判定するための方法

Publications (2)

Publication Number Publication Date
JP2017526629A true JP2017526629A (ja) 2017-09-14
JP2017526629A5 JP2017526629A5 (enExample) 2018-12-06

Family

ID=51162662

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016575341A Withdrawn JP2017526629A (ja) 2014-06-27 2015-06-26 血液系悪性腫瘍を治療、診断および予後判定するための方法
JP2020019451A Active JP6846551B2 (ja) 2014-06-27 2020-02-07 血液系悪性腫瘍を治療、診断および予後判定するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020019451A Active JP6846551B2 (ja) 2014-06-27 2020-02-07 血液系悪性腫瘍を治療、診断および予後判定するための方法

Country Status (15)

Country Link
US (4) US10195207B2 (enExample)
EP (2) EP2959904A1 (enExample)
JP (2) JP2017526629A (enExample)
KR (1) KR102628235B1 (enExample)
CN (1) CN106471373B (enExample)
AU (2) AU2015279105B2 (enExample)
BR (1) BR112016029562B1 (enExample)
CA (1) CA2953272C (enExample)
DK (1) DK3160472T3 (enExample)
ES (1) ES2796056T3 (enExample)
IL (1) IL249579B (enExample)
MX (1) MX362049B (enExample)
RU (1) RU2727418C2 (enExample)
WO (1) WO2015197839A1 (enExample)
ZA (1) ZA201700080B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562100B (zh) * 2016-07-28 2021-07-20 江苏亚虹医药科技股份有限公司 多巴胺β-羟化酶(DBH)抑制剂和血清素受体(5-HT)拮抗剂用于治疗癌症的用途
EP3348266A1 (en) * 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer
JP7002245B2 (ja) * 2017-08-10 2022-01-20 シスメックス株式会社 血液分析装置、血液分析方法およびプログラム
CN111886025A (zh) * 2017-11-01 2020-11-03 新加坡国立大学 血清素能药物治疗病毒诱发的血小板减少症的用途
AU2019208396B2 (en) 2018-01-18 2024-11-14 Leukos Biotech, S. L. Apomorphine·palmitic acid cocrystal solid particle crystalline form
US11034751B1 (en) 2018-01-30 2021-06-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using serotonin receptor inhibitors
CN111257558B (zh) * 2020-01-19 2021-08-24 江苏省人民医院（南京医科大学第一附属医院） 基于机器学习的慢性淋巴细胞白血病肿瘤细胞识别方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040055311A (ko) * 2002-12-20 2004-06-26 주식회사 피앤아이 컨설팅 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
NL300886A (enExample) 1962-11-23
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
DE602004014254D1 (de) * 2003-02-17 2008-07-17 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit 5-ht1f rezeptor verbundenen haematologischen krankheiten
WO2008098351A1 (en) * 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
WO2008146101A1 (en) 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases
NZ587292A (en) * 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
EP2433124B1 (en) * 2009-05-19 2017-03-01 Vivia Biotech S.L. Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2015079439A1 (en) * 2013-11-26 2015-06-04 Technion Research And Development Foundation Limited Neuronal modulation
US20150197839A1 (en) * 2014-01-13 2015-07-16 Maria Celeste Rellamas Tria Forming conductive pattern using titania sol-gel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040055311A (ko) * 2002-12-20 2004-06-26 주식회사 피앤아이 컨설팅 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. R. ACAD. SCI. III, vol. 324, no. 4, JPN6018045368, 2001, pages 365 - 372, ISSN: 0004135020 *
J. IMMUNOL., vol. 151, no. 3, JPN6018045364, 1993, pages 1175 - 1183, ISSN: 0004135019 *
J. PHARMACOBIO-DYN., vol. 13, JPN6018045362, 1990, pages 426 - 431, ISSN: 0004135018 *
NAT. GENET., vol. 36, no. 3, JPN6018045357, 2004, pages 257 - 263, ISSN: 0004135016 *
PROC. NATL. ACAD. SCI. USA, vol. 103, no. 36, JPN6018045359, 2006, pages 13485 - 13490, ISSN: 0004135017 *

Also Published As

Publication number Publication date
CA2953272C (en) 2022-10-04
RU2016147748A3 (enExample) 2019-02-13
MX2016016994A (es) 2017-06-09
JP6846551B2 (ja) 2021-03-24
ZA201700080B (en) 2019-04-24
EP3160472B1 (en) 2020-03-11
US20170143735A1 (en) 2017-05-25
CN106471373A (zh) 2017-03-01
US20220323456A1 (en) 2022-10-13
EP3160472A1 (en) 2017-05-03
CA2953272A1 (en) 2015-12-30
RU2016147748A (ru) 2018-08-03
US20210228593A1 (en) 2021-07-29
CN106471373B (zh) 2019-08-23
US10195207B2 (en) 2019-02-05
AU2020200010A1 (en) 2020-01-30
AU2015279105A1 (en) 2016-12-15
BR112016029562A2 (pt) 2017-08-22
US20190343843A1 (en) 2019-11-14
KR102628235B1 (ko) 2024-01-22
DK3160472T3 (da) 2020-06-02
AU2015279105B2 (en) 2019-10-03
BR112016029562B1 (pt) 2021-07-06
EP2959904A1 (en) 2015-12-30
AU2020200010B2 (en) 2020-11-19
KR20170021253A (ko) 2017-02-27
US11337984B2 (en) 2022-05-24
ES2796056T3 (es) 2020-11-25
RU2727418C2 (ru) 2020-07-21
IL249579A0 (en) 2017-02-28
MX362049B (es) 2019-01-04
WO2015197839A1 (en) 2015-12-30
JP2020097608A (ja) 2020-06-25
IL249579B (en) 2019-03-31

Similar Documents

Publication Publication Date Title
JP6846551B2 (ja) 血液系悪性腫瘍を治療、診断および予後判定するための方法
CN104634972B (zh) 抗cxcr1组合物和方法
CN107406881B (zh) 用于指导癌症治疗的内容相关的诊断测试
EP2771488B1 (en) Carbonic anhydrase ix-related markers and use thereof
CN109554469B (zh) T细胞急性淋巴性白血病的肿瘤细胞及其分子标志
WO2022159720A2 (en) Methods to quantify rate of clonal expansion and methods for treating clonal hematopoiesis and hematologic malignancies
JPWO2007018309A1 (ja) Ｒｂパスウェイ上の分子を指標とする化合物の評価方法及び分子診断方法
JP2025146792A (ja) 白血病の髄外浸潤マーカー
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
Gao et al. PB1817 A STUDY OF SERUM ALBUMIN AND CALCIUM IN 93 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
JP2023079470A (ja) 多発性骨髄腫の処置のための医薬組成物
BLASTS Myeloproliferative Disorders-Biology
WO2019006354A1 (en) METHODS FOR DETECTION AND REDUCTION OF COLONIZATION OF THE CENTRAL NERVOUS SYSTEM BY CANCER CELLS
HK1206256B (zh) 抗cxcr1组合物和方法

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20170502

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181029

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20181029

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20181101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20181129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200305